市場調查報告書

非霍奇金淋巴瘤治療市場:2019-2025

Non-Hodgkin lymphoma treatment Market 2019-2025

出版商 Orion Market Research Pvt Ltd 商品編碼 949657
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
非霍奇金淋巴瘤治療市場:2019-2025 Non-Hodgkin lymphoma treatment Market 2019-2025
出版日期: 2020年06月27日內容資訊: 英文
簡介

在預測期內,預計全球非霍奇金淋巴瘤治療市場將顯著增長。非霍奇金淋巴瘤是由白細胞引起的,並影響人體免疫系統的一部分。非霍奇金淋巴瘤的治療取決於幾個因素,包括年齡,非霍奇金淋巴瘤的類型和非霍奇金淋巴瘤的分期。諸如治療行業研發活動增加以及非霍奇金淋巴瘤患病率上升等因素推動了非霍奇金淋巴瘤治療市場的發展。根據英國《 2017年癌症研究》的數據,每年英國約有14,100例非霍奇金淋巴瘤新病例登記。

全球非霍奇金淋巴瘤治療市場是根據細胞類型和治療類型分類的。按照細胞類型,市場分為B細胞淋巴瘤和T細胞淋巴瘤。 B細胞非霍奇金淋巴瘤的治療很大程度上取決於疾病的亞型和分期。通常,化學療法和放射療法是B細胞非霍奇金淋巴瘤的兩種主要治療方法。按照治療類型,市場可細分為免疫療法,化學療法,靶向療法,放射療法和乾細胞移植。

從地理上講,《全球非霍奇金淋巴瘤治療市場報告》的研究依據是北美(美國和加拿大),歐洲(英國,德國,意大利,西班牙,法國和其他歐洲),亞太地區(中國,日本,印度)和其他地區。預計在預測期內,北美將佔有很大的市場份額。預計在預測期內,亞太地區將在全球非霍奇金淋巴瘤治療市場中顯示出顯著增長。

本報告調查了全球非霍奇金淋巴瘤治療市場,提供了該市場的概況以及按細胞類型,治療,區域和進入市場的公司概況的趨勢。

內容

第1章報告概述

第2章市場概述和見解

  • 調查範圍
  • 分析師見解和當前市場趨勢
  • 規則與規定

第3章競爭情況

  • 主要策略分析
  • 主要公司分析
    • AbbVie Inc.
    • AstraZeneca PLC
    • Seattle Genetics Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Novartis International AG

第4章市場決定因素

  • 動機
  • 抑制因子
    • 市場機會

第5章市場細分

  • 按細胞類型分類的非霍奇金淋巴瘤治療市場
    • B細胞
    • T細胞
  • 按類型劃分的非霍奇金淋巴瘤治療市場
    • 化學療法
    • 放療
    • 其他

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第7章公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • Epizyme, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Nordic Nanovector ASA
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Seattle Genetics, Inc.
  • Sorrento Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: OMR2021976

Global Non-Hodgkin lymphoma treatment Market Size, Share & Trends Analysis Report By Cell Type (B-Cell and T-Cell), By Therapy Type (Chemotherapy, Radiation Therapy, and Others), and Forecast 2019-2025

The global Non-Hodgkin lymphoma treatment market is anticipated to grow significantly during the forecast period. Non-Hodgkin lymphoma originates from the white blood cell and affects the parts of the body's immune system. Treatment of Non-Hodgkin lymphoma depends on the several factors such as age, type of Non-Hodgkin lymphoma, and stage of Non-Hodgkin lymphoma. The factor such as increasing R&D activities in therapeutics drugs industry coupled with the increasing prevalence of Non-Hodgkin lymphoma disease will drive Non-Hodgkin lymphoma treatment market. According to Cancer Research UK in 2017, around 14,100 new non-Hodgkin lymphoma cases are registered every year in the UK.

The global Non-Hodgkin lymphoma treatment market is segmented on the basis of Cell type and therapy type. Based on cell type, the market is bifurcated into B-Cell lymphoma and T-Cell lymphoma. The treatment of B-cell Non-Hodgkin lymphoma is mainly based on the subtype and stage of the disease. In general, chemotherapy and radiation therapy are the two principal forms of treatment for B-cell Non-Hodgkin lymphoma. Based on the therapy type, the market is sub-segmented into immunotherapy, chemotherapy, targeted therapy, radiation, and stem cell transplant.

Geographically, the study of the global Non-Hodgkin lymphoma treatment market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. North America is estimated to contribute a significant share in the market during the forecast period. Asia-Pacific is estimated to exhibit a significant growth rate in the global Non-Hodgkin lymphoma treatment market during the forecast period.

Moreover, the study of the global Non-Hodgkin lymphoma treatment market report covers the analysis of various players operating in the market. Some of the key players covered in the report include AbbVie Inc., AstraZeneca PLC, Novartis International AG, Seattle Genetics, Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Merck & Co., Inc., Bayer AG, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., and others. The market players are considerably contributing to the market growth by adopting various strategies to stay competitive in the market.

Research Methodology

The market study of the Non-Hodgkin lymphoma treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for working in Lymphoma landscape, pharmaceutical companies, drug manufacturers, medical device companies, healthcare industry, research organizations, academic institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis by Cell Type

2. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis by Therapy Type

The Report Covers:

  • Comprehensive research methodology of the Non-Hodgkin lymphoma treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Non-Hodgkin lymphoma treatment market.
  • Insights about market determinants which are stimulating the Non-Hodgkin lymphoma treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Key Strategy Analysis
  • 3.2. Key Company Analysis
    • 3.2.1. AbbVie Inc.
      • 3.2.1.1. Overview
      • 3.2.1.2. Financial Analysis
      • 3.2.1.3. SWOT Analysis
      • 3.2.1.4. Recent Developments
    • 3.2.2. AstraZeneca PLC
      • 3.2.2.1. Overview
      • 3.2.2.2. Financial Analysis
      • 3.2.2.3. SWOT Analysis
      • 3.2.2.4. Recent Developments
    • 3.2.3. Seattle Genetics Inc.
      • 3.2.3.1. Overview
      • 3.2.3.2. Financial Analysis
      • 3.2.3.3. SWOT Analysis
      • 3.2.3.4. Recent Developments
    • 3.2.4. Teva Pharmaceuticals Industries Ltd.
      • 3.2.4.1. Overview
      • 3.2.4.2. Financial Analysis
      • 3.2.4.3. SWOT Analysis
      • 3.2.4.4. Recent Developments
    • 3.2.5. Novartis International AG
      • 3.2.5.1. Overview
      • 3.2.5.2. Financial Analysis
      • 3.2.5.3. SWOT Analysis
      • 3.2.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
    • 4.1. Opportunities

5. Market Segmentation

  • 5.1. Non-Hodgkin Lymphoma Treatment Market by Cell Type
    • 5.1.1. B-Cell
    • 5.1.2. T-Cell
  • 5.2. Non-Hodgkin Lymphoma Treatment Market by Therapy Type
    • 5.2.1. Chemotherapy
    • 5.2.2. Radiation Therapy
    • 5.2.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. US
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Amgen Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Bayer AG
  • 7.5. Bristol Myers Squibb Co.
  • 7.6. Eli Lilly and Co.
  • 7.7. Epizyme, Inc.
  • 7.8. F. Hoffmann-La Roche Ltd.
  • 7.9. Gilead Sciences, Inc.
  • 7.10. GlaxoSmithKline PLC
  • 7.11. Johnson & Johnson Services Inc.
  • 7.12. Merck & Co., Inc.
  • 7.13. Nordic Nanovector ASA
  • 7.14. Novartis International AG
  • 7.15. Pfizer Inc.
  • 7.16. Sanofi SA
  • 7.17. Seattle Genetics, Inc.
  • 7.18. Sorrento Therapeutics, Inc.
  • 7.19. Spectrum Pharmaceuticals, Inc.
  • 7.20. Takeda Pharmaceutical Co. Ltd.
  • 7.21. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 2. GLOBAL B-CELL LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL T-CELL LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
  • 5. GLOBAL CHEMOTHERAPY FOR NON-HODGKIN LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL RADIATION THERAPY FOR NON-HODGKIN LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL OTHER THERAPY FOR NON-HODGKIN LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 9. NORTH AMERICAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 10. NORTH AMERICAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 11. NORTH AMERICAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
  • 12. EUROPEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 13. EUROPEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 14. EUROPEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
  • 15. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 16. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
  • 18. REST OF THE WORLD NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 19. REST OF THE WORLD NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE BY CELL TYPE, 2018 VS 2025 (%)
  • 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE BY THERAPY TYPE, 2018 VS 2025 (%)
  • 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ROE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)